Natco Pharma Q1 FY27: Profit down 57%, dividend set

Results snapshot: a weak June quarter

Natco Pharma reported a weak set of numbers for the June quarter of FY27, with profitability and topline both falling sharply year-on-year. Consolidated net profit for Q1 FY27 was reported at ₹206.5 crore to ₹207 crore, down 57% from ₹480.3 crore to ₹481 crore in the year-ago period. Revenue also declined steeply, with multiple figures cited across disclosures and reports for the quarter. Revenue from operations was reported at around ₹735.2 crore to ₹735 crore, versus about ₹1,328.9 crore to ₹1,329 crore a year earlier. Separately, consolidated total revenue was reported at ₹794.4 crore, down from ₹1,390.6 crore in Q1 FY26.

The primary reason cited for the decline was lower sales of lenalidomide, a key product in the company’s portfolio. Even as the quarter reflected pressure from this drop, the company also pointed to growth in parts of its base business in India and overseas. The earnings release period also included board decisions on shareholder payouts and capital-raising flexibility.

Key driver highlighted: lower lenalidomide sales

Several reports tied the revenue contraction to a fall in lenalidomide sales during the quarter. The decline in this product category weighed on international formulations, which form a large part of the overall revenue mix. While the company’s base business was described as showing double-digit growth, the impact from lenalidomide was large enough to pull down consolidated revenue significantly year-on-year.

This context matters because Natco’s quarterly performance can swing based on the scale and timing of large products in overseas markets. In Q1 FY27, the narrative across sources remained consistent on the trigger: lenalidomide revenue was lower than the comparable quarter last year.

Profitability metrics: EBITDA and margins diverge across sources

Operating performance was also reported under pressure, though the exact EBITDA figure differs across cited summaries. One set of reported numbers showed EBITDA declining 67.4% year-on-year to ₹186 crore from ₹571 crore, with an EBITDA margin of 25.3% versus 43% a year earlier. Another set of figures stated EBITDA including other income at ₹245.7 crore, with an EBITDA margin of 30.9%.

The gap indicates that different reporting lines or inclusions (such as other income) were being referenced in various summaries. What is consistent is that the quarter saw a sharp year-on-year step-down in operating profits relative to the high base in Q1 FY26.

Segment detail: international formulations hit hardest

A segment split reported for Q1 FY27 showed international formulations revenue at ₹477.1 crore, down from ₹1,120.9 crore in Q1 FY26. Domestic formulations revenue was reported at ₹136.4 crore, up from ₹107.0 crore. API revenue was reported at ₹66.7 crore, up from ₹52.6 crore.

These figures underline how the global business, including profit share and subsidiaries, drove most of the year-on-year decline. At the same time, the domestic formulations and API lines were reported to have grown from the previous year’s quarter. The mix shift helps explain why consolidated performance can weaken even when some underlying segments expand.

Associate contribution: Adcock Ingram added to profits

The associate company, Adcock Ingram, was reported to have contributed ₹84.3 crore to profits. This data point is notable because it provides a quantified contribution outside Natco’s core operating lines. In quarters where core profitability is pressured, associate income can materially influence the consolidated profit print.

Interim dividend announced: record date and payment schedule

Despite the weaker quarter, the board declared an interim dividend of ₹1.50 per equity share for the financial year 2026-27. The equity shares have a face value of ₹2 each, and the declared interim dividend was described as 75% of face value. Shareholders on record as of August 20, 2026, will be eligible for the dividend.

Payments are scheduled to commence from August 26, 2026. The dividend announcement was approved at a board meeting held on August 14, 2026.

Fund-raise approval: up to ₹2,000 crore across instruments

The board also approved a proposal to raise up to ₹2,000 crore, subject to necessary approvals. The routes mentioned across reports included a qualified institutional placement (QIP) and/or other permitted instruments. Another summary noted that the exploration could include public issues, preferential issues, rights issues, or private placements.

This approval does not by itself confirm an immediate issuance, but it establishes the ceiling and the board’s intent to keep financing options open. Investors typically track such proposals for potential dilution, timing, and the stated use of proceeds once disclosed.

Market reaction: stock down on the day

Following the results, the stock was reported to have fallen 5.1% to ₹903.15 from the previous close of ₹951.70. The move left the share price well below its 52-week high, as noted in the same market update.

The decline reflects the market’s immediate reaction to the earnings contraction and the revenue miss relative to the prior year base. It also coincided with the announcement of a possible fund raise, which can influence near-term sentiment depending on perceived dilution risk and capital needs.

Key figures table: Q1 FY27 vs Q1 FY26

Why this quarter matters: base effect and product concentration

The Q1 FY27 comparison was against a period when lenalidomide revenues were materially higher, which amplified the year-on-year decline. The reported split shows international formulations as the largest contributor to the drop, consistent with product concentration risk in certain quarters. At the same time, the domestic formulations and API lines were reported to have grown, suggesting that parts of the base portfolio remained resilient.

Another contextual item in the disclosures was the comparison to Q4 FY26, where consolidated profit after tax was cited at ₹269 crore and included a one-time benefit of ₹115 crore linked to remeasurement of deferred tax assets after the decision to move to the new tax regime from FY 2027. This highlights how one-off items can affect quarter-to-quarter comparisons in addition to operating drivers.

What to watch next

Near-term focus will likely remain on the trajectory of lenalidomide-linked revenues and how the mix evolves across international and domestic lines. Investors will also track the next steps on the proposed fund raise up to ₹2,000 crore, including the chosen instrument, timing, and any stated objectives. On the shareholder returns side, the key dates are already set, with the interim dividend record date on August 20, 2026, and payments beginning August 26, 2026.